Your search for dabigatran returned 5 results

Supratherapeutic plasma levels of dabigatran etexilate do not prolong QTc intervals of the electrocardiogram (ECG), as reported from a study presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Neurologists, internists and cardiologists differ markedly in their prescribing beliefs when it comes to the prevention of ischemic stroke due to atrial fibrillation, according to survey results.

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.